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Development of t cell immunity to 
norovirus and rotavirus in children 
under five years of age
Maria Malm1, Heikki Hyöty2, Mikael Knip3,4,5,6, timo Vesikari1 & Vesna Blazevic1
Most of the research effort to understand protective immunity against norovirus (NoV) has focused on 
humoral immunity, whereas immunity against another major pediatric enteric virus, rotavirus (RV), has 
been studied more thoroughly. The aim of this study was to investigate development of cell-mediated 
immunity to NoV in early childhood. Immune responses to NoV GI.3 and GII.4 virus-like particles and 
RV VP6 were determined in longitudinal blood samples of 10 healthy children from three months to 
four years of age. Serum IgG antibodies were measured using enzyme-linked immunosorbent assay 
and production of interferon-gamma by peripheral blood T cells was analyzed by enzyme-linked 
immunospot assay. NoV-specific T cells were detected in eight of 10 children by the age of four, with 
some individual variation. T cell responses to NoV GII.4 were higher than those to GI.3, but these 
responses were generally lower than responses to RV VP6. In contrast to NoV-specific antibodies, T cell 
responses were transient in nature. No correlation between cell-mediated and antibody responses was 
observed. NoV exposure induces vigorous T cell responses in children under five years of age, similar to 
RV. A role of T cells in protection from NoV infection in early childhood warrants further investigation.
Noroviruses (NoVs) and rotaviruses (RVs) are leading causes of severe acute gastroenteritis (AGE) in children 
under five years of age1. RV has been a major cause of AGE requiring hospitalization in children but as a con-
sequence of implementing RV vaccination in >100 countries since 2006, a trend toward NoV predominance 
is seen2,3. Analysis of NoV-specific antibodies in early childhood indicated ~50% prevalence at the age of 7–12 
months that increased to over 90% by the age of five years in Finland4. There is no vaccine available against NoV 
but two experimental NoV vaccines are in clinical phase5,6 and several in preclinical development7–9.
NoV contains 90 copies of dimeric capsid VP1 proteins that spontaneously form virus-like particles (VLPs) 
in vitro10. Unlike RV, NoV research lacks efficient cell culture system for virus propagation and thereby most 
immunological assays, such as surrogate neutralization assay as well as vaccine development, rely on antigenically 
and morphologically equivalent NoV VLPs11. Recently there has been progress with human intestinal enteroids 
(HIE) that have been utilized to replicate NoV in vitro, allowing e.g. to measure neutralizing antibodies for NoV 
with enteroid culture system12,13. Antigenic heterogeneity is a major issue in NoV protection, contributing to the 
lack of cross-protection between genogroup I (GI) and genogroup II (GII) NoVs and limited immunity between 
heterogenous strains within these genogroups14–16. Even though there are over 30 genotypes of NoVs infecting 
humans, for the last two decades GII.4 variants have caused majority of NoV infections17–19.
NoVs and RVs2,20 use polymorphic set of histo-blood group antigen (HBGA) molecules expressed on gut epi-
thelium as cell attachment factors/receptors in strain-specific manner21. Genetic variability of HBGA expression 
patterns between individuals and subsequent different innate susceptibility to infections complicates interpre-
tation of immune responses and vaccine efficacy studies. For example, individuals with non-secretor status lack 
expression of certain HBGA molecules essential for infectivity of several NoV strains and thereby are less prone 
to NoV infections2.
Despite extensive research, immunological mechanisms of protection against NoV and RV infections or vacci-
nation remain unclear22,23. RV humoral and cell-mediated immunity (CMI) has been thoroughly investigated and 
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data supporting the protective role of IgA24,25, neutralizing antibodies26 and T cells27–31 is exhaustive. However, 
there is still much controversy and debate over the protective effect of these immunological components24,32.
For both NoV and RV, the presence of high preexisting antibody titers in serum may indicate less severe 
disease and show some correlation with protection33–35. We have previously described the development of 
NoV-specific IgG responses in the first years of life and found correlation between high strain-specific serum IgG 
and antibodies blocking HBGA binding to protection from NoV infection4,34,36. However, the results also sug-
gested that antibody response was short-lasting and strain-specific therefore not able to protect from subsequent 
heterologous NoV infections16,37.
There is evidence from animal models and human studies that RV-specific T cells play a role in viral clear-
ance38, that may be mediated e.g. by secretion of interferon-gamma (IFN-γ). RV infection induces both CD4+ 
and CD8+ T cell responses, however, the level is much lower compared to other viruses such as cytomegalovi-
rus29,39–41. While human NoV-specific serology is thoroughly investigated, there are very few publications on 
human NoV-specific CMI responses42–45. Our recent research on NoV-specific T cell responses showed that in 
addition to antibodies circulating NoV-specific memory T cells are present in healthy adults45. Two human stud-
ies have described CD4+ T cells after NoV challenge43,44 and after oral NoV VLP vaccine administration42. In the 
present study NoV-specific T cell responses in children under five years of age were investigated for the first time.
Results
Serum IgG levels to NoV and RV increase by the age. Serum IgG antibody levels against NoV GI.3 
and GII.4 VLPs and RV VP6 at the age 3, 6, 12, 24, 36 and 48 months were analyzed using ELISA. IgG end-point 
titers stratified according to age are shown in Fig. 1a–c. Antibody levels to all tested antigens increased until the 
age of 2–3 years and remained at high levels at the age of four years. During the study period all children serocon-
verted to NoV, either to GI.3 or GII.4 or both, while eight of 10 subjects seroconverted to RV VP6 (Tables 1–3). 
Lowest levels of NoV (Fig. 1a,b) and RV (Fig. 1c) –specific antibodies were observed at the age of 6 or 12 months 
following the decrease of maternal antibodies, but the age of observed seroconversion varied from 1 to 4 years of 
age (Table 3).
NoV-specific maternal IgG antibodies were detected in all subjects at the age of 3 months with geometric 
mean titers (GMT) 734 for GI.3 (Fig. 1a) and 1234 for GII.4 (Fig. 1b). IgG levels decreased by the age of 6 months 
(GMT 459 for GI.3 and 696 for GII.4) with no significant change by the 12 months of age (GMTs 566 for GI.3 
and 746 for GII.4). A significant increase of NoV GI.3 (Fig. 1a) and GII.4 (Fig. 1b) IgG was observed by the age of 
2–3 years (Fig. 1a,b). Both GI.3 (Fig. 1a) and GII.4-specific (Fig. 1b) IgG end-point titers increased by the age of 
four (GMT 1853 for GI.3 and 2601 for GII.4) although the difference was not statistically significant (p > 0.05). 
Seven of 10 subjects seroconverted to NoV by the three years of age and the remaining three subjects by the age 
of four (Table 1).
RV VP6-specific serum IgG levels were high at the 3 months of age (GMT 1600) and decreased by the 6 
months of age (GMT 985) when maternal antibodies had vanished (Fig. 1c). No significant change in the GMT 
from 6 months to 12 months of age (GMT 1970) was detected. A significant increase (p < 0.05) was detected 
from 6 months to the 2–3 years age (GMT 2907) and the trend was increasing by the age, similarly to NoV IgG 
(Fig. 1a,b). Seroconversion to RV was detected in eight of 10 subjects during the study period, four at 12 months 
of age and four subjects at 2–3 year old (Table 1).
NoV and RV induce transient T cell responses in children. T cell responses to NoV GI.3 VLP, NoV 
GII.4 VLP and RV VP6 developed in a paralleling fashion, as analyzed by ELISPOT IFN-γ (Fig. 2). Five of 10 
subject had positive response to NoV and six subjects to RV within the first year of life (Fig. 2 and Table 2). By 
the age of 4 years only two donors (subject 1 and 2) did not respond to NoV VLPs, and only one subject did not 
respond to RV VP6 (subject 1). Transient although not statistically significant (p > 0.05) increase in the magni-
tude of the T cell responses to NoV and RV was observed by the age of 2–3 years, decreasing then by the age of 
four (Fig. 2). Mean ELISPOT IFN-γ values by the age stratification for NoV GII.4 were 36 at ≤12 months, 90 at 
2–3 years and 50 SFC/106 cells at 4 years and congruently with the antibody results, GI.3-specific T cell responses 
were significantly lower (p = 0.01) (the means: 13, 36 and 31 SFC/106 cells) (Fig. 2). IFN-γ responses to RV VP6 
were significantly higher (p = 0.005) than NoV-specific responses, mean values being 88, 183 and 59 SFC/106 
cells in the corresponding ages (Fig. 2c). Subject 5 (RV vaccinated) generated the strongest VP6-specific T cell 
responses, and had also the highest NoV-specific T cell responses (Fig. 2). PBMCs of all donors produced IFN-γ 
after the PHA stimulation (>1000 SFC/106 PBMCs).
Discussion
Antibody responses to NoV and RV have been studied extensively, and while there are publications on T 
cell-mediated responses to RV in both children and adults29–31,40,41,46, cellular immunity to NoV is investigated 
in adults42,44,45 but remained uncharacterized in young children. Here we investigated the development of T cell 
responses together with humoral immunity in early childhood towards both NoV and RV.
Consistent with the predominance of GII.4 NoVs worldwide17 and in Finland19,47, and previous reports show-
ing increased prevalence of NoV-specific antibodies with increasing age in children4,33,34, seroconversion to GII.4 
was observed in all subjects analyzed in this study. The high prevalence of GII.4 NoV was reflected similarly to 
cell-mediated responses, where magnitude of T cell responses to GII.4 was notably higher than to GI.3. GI.3 was 
chosen as a representative strain in this study, as it was the most prevalent GI NoV circulating in Finland during 
the study period19. Nevertheless, as the GII.4 strain used in here has not widely circulated during the study years 
2002–200747, the responses measured probably reflect cross-reactive responses and may be an underestimate 
of the total responses. Serum antibody responses to RV in the present study were analyzed using recombinant 
VP6 protein that induces comparable results to whole RV in ELISA25,48. The majority of RV-specific antibodies 
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are likely directed to highly immunogenic and conserved RV VP649 and seroconversion was observed in 80% of 
subjects during the study period.
While the cause of reported acute gastroenteritis in the study donors was not determined by the PCR or 
ELISA, seroconversion was the best marker for presumed infection, as described earlier30,34,35,37. However, sero-
conversion is not always an adequate measure and some infections may be missed. For instance, the subjects 5 
and 7 had NoV- and RV-specific T cell responses already at 12 months of age, indicating early virus exposure, but 
seroconverted to NoV only at the age of 2 and 4 years, respectively, and no seroconversion to RV was detected at 
Figure 1. Norovirus (NoV)- and rotavirus (RV)-specific serum immunoglobulin G (IgG) end-point titers. Sera 
were titrated with 2-fold serial dilutions and IgG antibodies were analyzed against NoV GI.3 (a), NoV GII.4 
(b) and RV VP6 (c) in enzyme-linked immunosorbent assay. Shown are end-point titers at the age of 3, 6 and 
12 months, mean end-point titers at 2–3 years and 4 years of age. The horizontal line indicates geometric mean 
titer. Statistical differences were determined using Fisher’s exact test, and a p value of ≤0.05 was considered 
statistically significant (*). Each symbol denotes an individual child (▲ = Subject 1, ♦ = 2, ○ = 3, □ = 4, ×  = 5, 
Δ = 6, • = 7, ◊ = 8, ■ = 9, * = 10).
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all. Similarly, Mäkelä et al. reported a child with strong proliferative T cell responses to RV without increase in RV 
antibodies30. Moreover, when measuring virus-specific T cell responses in infants and small children, passively 
acquired maternal antibodies are not interfering with the results interpretation and in this respect, T cells may be 
better marker for the infection.
Following RV infection children develop T cells responses that can be detected in peripheral blood40. Due to 
the low cell numbers, it was necessary to pool PBMC samples of two time points (6 and 12 months, 2 and 3 years), 
which may have led to underestimation of some immune responses if one of the pooled sample has been negative. 
However, we assume that the effect is not critical, as pooled sample time points are relatively close to each other. 
In addition, T cell responses at the age of four were lower, than responses obtained with pooled cells from 2–3 
years of age. In the present study the development of both NoV- and RV-specific T cell responses measured by 
IFN-γ cytokine secretion, showed a similar trend increasing by the age to 2–3 years, followed by a decrease at 4 
years. This type of transient T cell immunity to RV in children has been reported earlier30, and our results suggest 
that NoV-specific T cell responses may follow the same pattern, being similarly short lasting. The acute nature 
of both NoV and RV infections may induce low frequency of memory T cells, compared to prolonged infections 
such as herpesvirus50 and furthermore, small children are even less likely to have circulating memory cells due to 
the limited exposure history and less developed immune system51. In contrast, once reaching high levels, antibody 
responses to NoV and RV remained high. It could be speculated that protection by NoV-specific antibodies could 
result in dampening of T cell responses by the age of 4 years. Unfortunately, there are no results on correlation of 
protective NoV blockade antibody titers and T cell responses published so far. However, large number of subjects 
and well controlled NoV challenge study would be needed to answer this more reliably. Congruently to our pre-
viously published NoV-specific immune responses in adults45, there was no correlation between seroconversion 
and CMI responses to either NoV or RV (Tables 1, 2, respectively).
The results indicate high individual variation in immune responses to NoV and RV at an early age. This vari-
ation can only partly be explained by previous exposure history suggesting that individual variation in immune 
responsiveness may play a role. The results of the two subjects (Subject 1 and 5) that received three doses of RV 
Donor
12 mo 2–3 y 4 y
NoV GI.3/GII.4 RV NoV GI.3/GII.4 RV NoV GI.3/GII.4 RV
1a −/+ — +/− + +/− +
2 −/+ + +/+ — −/− —
3b −/− — +/+ + +/− —
4 −/− — −/+ + −/+ +
5a −/− — +/+ — −/− —
6 −/− + −/− + −/+ —
7 −/− — −/− — −/+ —
8 −/− — −/− + +/− —
9 −/− + −/+ — −/− +
10 −/− + −/+ — −/+ —
Table 1. Seroconversion to norovirus (NoV) and to rotavirus (RV) at different age. aReceived RV vaccine  
(3 doses) before 6 months of age. bReceived RV vaccine (1 dose) before 3 months of age. −, no seroconversion 
(<four-fold increase in IgG end-point titer of sequential serum samples). +, seroconversion (≥four-fold 
increase in IgG end-point titer of sequential serum samples).
Donor
≤12 mo 2–3 y 4 y
NoV GI.3/GII.4 RV NoV GI.3/GII.4 RV NoV GI.3/GII.4 RV
1a −/− — −/− N/A +/− —
2 −/− — −/− + N/A N/A
3b −/− — −/− — +/+ +
4 −/− — −/+ + +/− +
5a +/+ + +/+ + +/+ +
6 −/+ + N/A N/A N/A N/A
7 −/+ + +/+ + +/− +
8 −/+ + +/+ + +/+ +
9 −/+ + N/A/+ + N/A/— N/A
10 −/− + −/+ + +/+ +
Table 2. Positive IFN-γ responses to norovirus (NoV) and to rotavirus (RV) at different age. aReceived RV 
vaccine (3 doses) before 6 months of age. bReceived RV vaccine (1 dose) before 3 months of age. −, a negative 
readout (below the cut-off level) in ELISPOT IFN-γ assay. +, a positive readout (above the cut-off level) in 
ELISPOT IFN-γ assay. N/A, not available.
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vaccine before the age of six months illustrate an example of challenging interpretation of the results in epide-
miological and vaccine efficacy studies, interfered by the complexity of human immune system and different 
innate susceptibility to viruses. One of them (Subject 1) developed high and stable RV IgG response following 
Figure 2. Norovirus (NoV)- and rotavirus (RV)-specific interferon gamma (IFN-γ) production by T cells. 
Peripheral blood mononuclear cells (PBMC) were stimulated o/n with NoV GI.3 (a) and GII.4 (b) VLPs and 
RV VP6 (c) (30 µg/ml each) and cytokine production analyzed by enzyme-linked immunospot (ELISPOT) 
assay. Due to the shortage of cells, PBMCs collected at the age of 6 and 12 months and 2 and 3 years were pooled. 
Shown are mean IFN-γ spot-forming cells (SFC)/106 PBMCs of two replicate wells of an individual sample. The 
horizontal line indicates the mean of the age grouped samples. The dashed line represents the positivity cut off 
(≥26 SFC/106 PBMCs). Statistical differences between the groups were determined by a Mann-Whitney U test, 
and a p value of ≤0.05 was considered statistically significant.
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RV vaccination, however, no CMI response to RV was detected. His NoV-specific IgG responses remained excep-
tionally low throughout the whole study period that could be due to genetic background of this subject such 
as non-secretor status and HBGA type (not determined in this study). In contrast, Subject 5 also received RV 
vaccination at full schedule, but did not seroconvert to RV throughout the study, whereas CMI response to VP6 
was high already in the first year of life. NoV-specific immune responses of Subject 5 followed similar pattern to 
RV-specific responses, with negligible humoral response but exceptionally high CMI response. In addition, three 
other subjects (6, 7 and 8) also developed T cell responses to NoV and RV without the seroconversion in the first 
year of life, suggesting that these children primarily respond through CMI rather than humoral response to both 
AGE viruses.
Even though the number of the subjects is quite low, this study provides novel information on cell-mediated 
immune responses to NoV in this highly susceptible human population. The results suggest that NoV-specific T 
cell responses are generated already at an early age, and may have a role in protection similarly to what has been 
suggested for RV-specific T cells. The transient nature of the CMI responses indicates that serial infections may 
be needed for the development of stable memory T cell population. Furthermore, it remains to be seen if NoV 
VLP based vaccine could induce CMI responses capable to contribute to the protection against these infections.
Methods
Study samples. Ten children taking part in the Type I Diabetes Prediction and Prevention (DIPP) study52 
were prospectively followed for development of NoV- and RV-specific immune responses for four years. The 
DIPP study follows children with increased genetic risk for type 1 diabetes from birth and its protocol has been 
approved by the ethics committee of the Pirkanmaa Hospital District (Permit number: 97193M). A written 
informed consent to the study has been obtained from the parents of participating families, and all research was 
performed in accordance with relevant guidelines and regulations. Blood samples were collected at 3, 6, 12, 24, 
36 and 48 month of age. Diarrheal history of each subject indicated that all donors, except #2, had at least one 
episode of diarrhea reported before the age of 3 years, however the cause of acute gastroenteris was not deter-
mined. Although the samples were collected in 2002–2007, before introduction of RV vaccination to national 
immunization program, two of the subjects had received full vaccination series (Subjects 1 and 5) and one subject 
(Subject 3) received only the first dose. Plasma fractions were stored at −70 °C until analyzed. Peripheral blood 
mononuclear cells (PBMCs) were separated using BD Vacutainer™ Glass Mononuclear Cell Preparation (CPT) 
Tubes (Fisher Scientific) according to manufacturer’s instructions. PBMCs were frozen in 10% DMSO in fetal 
bovine serum (FBS) to liquid nitrogen. Prior to analysis, PBMCs were thawed in the presence of benzonase (50 
U/ml), washed and resuspended in culture medium (CM) containing RPMI 1640 with Glutamax® and HEPES 
(Gibco™ by Thermo Fisher Scientific) supplemented with 10 µg/ml Gentamicin (Gibco™) and 10% fetal bovine 
serum (FBS, Sigma-Aldrich, St. Louis, USA).
Recombinant protein antigens. NoV GI.3 (GenBank reference strain accession no. AF414403) and GII.4 
(AF080551) VLPs and RV VP6 protein (acc. no. GQ477131) used as antigens in analytical methods were pro-
duced by a baculovirus expression system (Invitrogen) in Spodoptera frugiperda (Sf9) insect cell cultures and 
purified as previously described7,53,54. The total protein concentration was quantified with Pierce® BCA Protein 
Assay (Thermo Scientific, Rockford).
NoV- and RV-specific IgG ELISA. Serum IgG antibody levels against NoV34 and RV55 were analyzed by 
ELISA as earlier described. Serum specimens were diluted two-fold starting at 1:100 and plated on NoV GI.3, 
GII.4 VLP or RV VP6 coated (1.0 µg/ml in phosphate-buffered saline, PBS) 96-well half-area microtiter plates 
(Corning Inc., Corning, NY) blocked with 5% skimmed milk in PBS. Serum dilutions were incubated on plates 
for 1 h at 37 °C. Bound antibodies were detected with goat anti-human IgG-HRP (Invitrogen, CA, USA) followed 
by o-phenylenediamine (OPD) substrate (Sigma-Aldrich, MO, USA) and H2O2. Optical density (OD) was meas-
ured at λ 490 nm using Victor2 1420 Multilabel Counter (Wallac, PerkinElmer) plate reader. Background signal 
from the blank wells (wells without serum) was subtracted from all of the OD readings on the plate. Each plate 
Donor
6 mo IgG titer Seroconversion IgG titer (age)
GI.3 NoV GII.4 NoV RV GI.3 NoV GII.4 NoV RV
1 100 50 1600 800 (2 ya) 400 (1 y) 6400 (3 y)
2 200 200 200 1600 (2 y) 800 (1 y) 3200 (1 y)
3 400 800 1600 1600 (2 y) 3200 (2 y) 6400 (2 y)
4 400 800 3200 — 6400 (3 y) 3200 (3 y)
5 400 400 400 3200 (2 y) 3200 (2 y) —
6 800 3200 800 — 6400 (4 y) 25600 (3 y)
7 1600 1600 1600 — 12800 (4 y) —
8 800 400 400 1800 (4 y) — 3200 (3 y)
9 800 1600 1600 — 1600 (3 y) 6400 (1 y)
10 400 1600 1600 — 3200 (3 y) 12800 (1 y)
Table 3. Serum norovirus (NoV) and rotavirus (RV)-specific IgG end-point titers and seroconversion. aAge at 
the seroconversion detected. −, no seroconversion detected.
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contained known NoV negative and positive control serum sample as an assay control. The cut-off value was 
determined as the mean OD reading of the negative control serum wells at a dilution 1:200 + 3 × standard error 
and at least 0.100 OD. End-point titer was expressed as a reciprocal of the final serum dilution giving an OD above 
the cut-off value. Seroconversion was defined as at least four-fold increase in the titer of successive sera.
NoV- and RV-specific ELISPOT IFN-γ. PBMCs were assayed in an IFN-γ ELISPOT assay according 
to previously described method45 with slight modifications. Briefly, ninety-six-well nitrocellulose filter plates 
(Millipore) were coated with anti-human IFN-γ capture antibody (Mabtech) and blocked with 10% FBS in CM. 
Thawed PBMCs were first rested o/n at +37 °C and 5% CO2 in CM. PBMC collected at 6 and 12 months and 
2 and 3 years of age were pooled for adequate cell number for the analysis. Cells were stimulated with 30 µg/
ml NoV VLPs (GI.3 or GII.4), 30 µg/ml RV VP6 protein, 50 µg/ml of phytohemagglutinin (PHA, positive con-
trol) or left unstimulated (CM only, negative control). PBMCs (0.2 × 106 cells/well) were plated with stimulants 
and incubated for 20 h at +37 °C and 5% CO2. Biotinylated anti-human IFN-γ antibody (Mabtech) followed by 
streptavidin-HRP (BD, New Jersey, USA) was used for detection. The spots were developed with Vector Nova 
Red substrate (Vector Labs, Burlingame, USA) and the plates were analyzed using ImmunoSpot Series II ana-
lyzer (CTL Europe, Leinfelden-Echterdingen, Germany). The results are expressed as mean spot forming cells 
(SFC)/106 PBMCs of the duplicate wells. A positive response (≥26 SFC/106 PBMC) was defined based on the 
averaged result of PBMCs isolated from the three months blood sample of several donors stimulated with NoV 
and RV antigens plus 3 × standard deviation (SD) (mean SFC/106 PBMC + 3 × SD).
Statistical analysis. Fisher’s exact test was used to compare the IgG end-point titers between age categories. 
Mann-Whitney U test of two independent samples was used to analyze ELISPOT IFN-γ results. All hypothesis 
tests were two-tailed. Statistical analyses were performed using IBM SPSS Statistics (SPSS, Chicago, IL) version 
23.0. Statistical significance was defined as a p < 0.05.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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